Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.66 USD 1.92% Market Closed
Market Cap: 76.8m USD
Have any thoughts about
Aerovate Therapeutics Inc?
Write Note

Intrinsic Value

AVTE's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one AVTE stock under the Base Case scenario is 4.24 USD. Compared to the current market price of 2.66 USD, Aerovate Therapeutics Inc is Undervalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AVTE Intrinsic Value
4.24 USD
Undervaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Aerovate Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AVTE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AVTE?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Aerovate Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Aerovate Therapeutics Inc

Provide an overview of the primary business activities
of Aerovate Therapeutics Inc.

What unique competitive advantages
does Aerovate Therapeutics Inc hold over its rivals?

What risks and challenges
does Aerovate Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Aerovate Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aerovate Therapeutics Inc.

Provide P/S
for Aerovate Therapeutics Inc.

Provide P/E
for Aerovate Therapeutics Inc.

Provide P/OCF
for Aerovate Therapeutics Inc.

Provide P/FCFE
for Aerovate Therapeutics Inc.

Provide P/B
for Aerovate Therapeutics Inc.

Provide EV/S
for Aerovate Therapeutics Inc.

Provide EV/GP
for Aerovate Therapeutics Inc.

Provide EV/EBITDA
for Aerovate Therapeutics Inc.

Provide EV/EBIT
for Aerovate Therapeutics Inc.

Provide EV/OCF
for Aerovate Therapeutics Inc.

Provide EV/FCFF
for Aerovate Therapeutics Inc.

Provide EV/IC
for Aerovate Therapeutics Inc.

Show me price targets
for Aerovate Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Aerovate Therapeutics Inc?

How accurate were the past Revenue estimates
for Aerovate Therapeutics Inc?

What are the Net Income projections
for Aerovate Therapeutics Inc?

How accurate were the past Net Income estimates
for Aerovate Therapeutics Inc?

What are the EPS projections
for Aerovate Therapeutics Inc?

How accurate were the past EPS estimates
for Aerovate Therapeutics Inc?

What are the EBIT projections
for Aerovate Therapeutics Inc?

How accurate were the past EBIT estimates
for Aerovate Therapeutics Inc?

Compare the revenue forecasts
for Aerovate Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aerovate Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aerovate Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aerovate Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Aerovate Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aerovate Therapeutics Inc with its peers.

Analyze the financial leverage
of Aerovate Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Aerovate Therapeutics Inc.

Provide ROE
for Aerovate Therapeutics Inc.

Provide ROA
for Aerovate Therapeutics Inc.

Provide ROIC
for Aerovate Therapeutics Inc.

Provide ROCE
for Aerovate Therapeutics Inc.

Provide Gross Margin
for Aerovate Therapeutics Inc.

Provide Operating Margin
for Aerovate Therapeutics Inc.

Provide Net Margin
for Aerovate Therapeutics Inc.

Provide FCF Margin
for Aerovate Therapeutics Inc.

Show all solvency ratios
for Aerovate Therapeutics Inc.

Provide D/E Ratio
for Aerovate Therapeutics Inc.

Provide D/A Ratio
for Aerovate Therapeutics Inc.

Provide Interest Coverage Ratio
for Aerovate Therapeutics Inc.

Provide Altman Z-Score Ratio
for Aerovate Therapeutics Inc.

Provide Quick Ratio
for Aerovate Therapeutics Inc.

Provide Current Ratio
for Aerovate Therapeutics Inc.

Provide Cash Ratio
for Aerovate Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Aerovate Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Aerovate Therapeutics Inc?

What is the current Free Cash Flow
of Aerovate Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aerovate Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aerovate Therapeutics Inc

Current Assets 90.6m
Cash & Short-Term Investments 88.7m
Other Current Assets 1.9m
Non-Current Assets 354k
PP&E 273k
Other Non-Current Assets 81k
Current Liabilities 10.3m
Accounts Payable 908k
Accrued Liabilities 8.4m
Other Current Liabilities 993k
Non-Current Liabilities 151k
Other Non-Current Liabilities 151k
Efficiency

Earnings Waterfall
Aerovate Therapeutics Inc

Revenue
0 USD
Operating Expenses
-90.3m USD
Operating Income
-90.3m USD
Other Expenses
5.6m USD
Net Income
-84.6m USD

Free Cash Flow Analysis
Aerovate Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AVTE Profitability Score
Profitability Due Diligence

Aerovate Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Aerovate Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

AVTE Solvency Score
Solvency Due Diligence

Aerovate Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Aerovate Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AVTE Price Targets Summary
Aerovate Therapeutics Inc

Wall Street analysts forecast AVTE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AVTE is 2.38 USD with a low forecast of 2.02 USD and a high forecast of 3.15 USD.

Lowest
Price Target
2.02 USD
24% Downside
Average
Price Target
2.38 USD
11% Downside
Highest
Price Target
3.15 USD
18% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AVTE?

Click here to dive deeper.

Dividends

Aerovate Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AVTE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AVTE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

76.8m USD

Dividend Yield

0%

Description

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.

Contact

MASSACHUSETTS
Boston
200 Berkeley Street, Floor 18
+16174432400.0
www.aerovatetx.com

IPO

2021-06-30

Employees

16

Officers

CEO & Director
Mr. Timothy P. Noyes M.B.A.
CFO & Treasurer
Mr. George A. Eldridge
Founder, President, COO & Secretary
Dr. Benjamin T. Dake Ph.D.

See Also

Discover More
What is the Intrinsic Value of one AVTE stock?

The intrinsic value of one AVTE stock under the Base Case scenario is 4.24 USD.

Is AVTE stock undervalued or overvalued?

Compared to the current market price of 2.66 USD, Aerovate Therapeutics Inc is Undervalued by 37%.

Back to Top